Get the Stockscreener App
3.92
23.27%
0.74
X 4 Pharmaceuticals Inc stock is traded at $3.92, with a volume of 3.25M.
It is up +23.27% in the last 24 hours and up +163.09% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.18
Open:
$3.15
24h Volume:
3.25M
Relative Volume:
0.87
Market Cap:
$44.72M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.4079
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
+37.54%
1M Performance:
+163.09%
6M Performance:
-72.03%
1Y Performance:
-82.81%
1-Day Range:
$3.1201
$3.9293
1-Week Range:
$2.45
$3.9293
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.92 | 28.41M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Multi asset correlation models including X4 Pharmaceuticals Inc.July 2025 News Drivers & AI Based Buy/Sell Signal Reports - Newser
Using data tools to time your X4 Pharmaceuticals Inc. exitJobs Report & AI Driven Stock Reports - Newser
Reversal indicators forming on X4 Pharmaceuticals Inc. stockMarket Activity Recap & Free Daily Entry Point Trade Alerts - Newser
Will X4 Pharmaceuticals Inc. continue its uptrendPortfolio Profit Report & High Yield Equity Trading Tips - Newser
Can swing trading help recover from X4 Pharmaceuticals Inc. lossesGap Down & Weekly Market Pulse Updates - Newser
Trend analysis for X4 Pharmaceuticals Inc. this weekJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - Newser
Is X4 Pharmaceuticals Inc. stock entering bullish territoryMarket Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Has X4 Pharmaceuticals Inc. formed a bullish divergenceMarket Movement Recap & Reliable Breakout Forecasts - Newser
Combining price and volume data for X4 Pharmaceuticals Inc.Trade Entry Summary & Weekly Watchlist of Top Performers - Newser
What Fibonacci levels say about X4 Pharmaceuticals Inc. reboundQuarterly Market Summary & Free High Return Stock Watch Alerts - Newser
Intraday pattern recognizer results for X4 Pharmaceuticals Inc.2025 Technical Patterns & Smart Investment Allocation Insights - Newser
Forecasting X4 Pharmaceuticals Inc. price range with options dataJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Using Bollinger Bands to evaluate X4 Pharmaceuticals Inc.Dollar Strength & Community Driven Trade Alerts - Newser
Is X4 Pharmaceuticals Inc. Forming a Bottom PatternJuly 2025 Snapshot & Weekly Market Pulse Updates - newsimpact.co.kr
Published on: 2025-08-18 06:28:48 - Newser
Published on: 2025-08-18 04:45:24 - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trendsTrade Analysis Report & Low Drawdown Trading Strategies - Newser
Momentum divergence signals in X4 Pharmaceuticals Inc. chartJuly 2025 Analyst Calls & Daily Technical Forecast Reports - Newser
How to use Fibonacci retracement on X4 Pharmaceuticals Inc.Market Trend Review & Stepwise Trade Signal Implementation - Newser
X4 Pharmaceuticals Inc. stock outlook for YEARPortfolio Performance Report & Accurate Buy Signal Alerts - Newser
Is X4 Pharmaceuticals Inc. forming a breakout patternQuarterly Market Summary & Growth Oriented Trading Recommendations - thegnnews.com
What analysts say about X4 Pharmaceuticals Inc. stock outlookJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - Newser
X4 Pharmaceuticals Inc.’s volatility index tracking explainedMarket Growth Summary & Verified Entry Point Detection - Newser
Published on: 2025-08-16 20:41:56 - Newser
X4 Pharmaceuticals Inc. stock trend outlook and recovery path2025 Market Overview & Trade Opportunity Analysis - Newser
Published on: 2025-08-16 03:30:19 - Newser
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Expands By 161.3% - Defense World
HC Wainwright Analysts Raise Earnings Estimates for XFOR - Defense World
X4 Pharmaceuticals Inc. stock daily chart insightsWeekly Volume Report & Technical Analysis for Trade Confirmation - Newser
How to integrate X4 Pharmaceuticals Inc. into portfolio analysis tools2025 Technical Overview & Weekly High Return Forecasts - Newser
Regression analysis insights on X4 Pharmaceuticals Inc. performanceGold Moves & High Accuracy Trade Alerts - Newser
Leading vs lagging indicators on X4 Pharmaceuticals Inc. performanceLong Setup & Expert Approved Momentum Trade Ideas - Newser
X4 Pharmaceuticals Grants Inducement Equity Awards to New Executive Officers - Quiver Quantitative
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
12.7 Million Shares: X4 Pharmaceuticals Awards Massive Option Grants to Three New Executive Officers - Stock Titan
Sector Rotation Brings X4 Pharmaceuticals Inc. Into FocusJuly 2025 Technicals & High Accuracy Investment Entry Signals - 선데이타임즈
Real time alert setup for X4 Pharmaceuticals Inc. performanceJuly 2025 Update & Real-Time Chart Pattern Alerts - Newser
Why X4 Pharmaceuticals Inc. stock attracts strong analyst attention2025 Sector Review & Smart Investment Allocation Insights - Newser
X4 Pharmaceuticals Closes $85M Private Placement Deal - The Globe and Mail
X4 Pharmaceuticals Plunges 13.99% on Price Target Cut - AInvest
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):